Results 281 to 290 of about 4,176,223 (397)
Machine learning-based algorithms applied to drug prescriptions and other healthcare services in the Sicilian claims database to identify acromegaly as a model for the earlier diagnosis of rare diseases. [PDF]
Crisafulli S+9 more
europepmc +1 more source
Prescription patterns of drugs of systemic use by dentists [PDF]
Lia Silva de Castilho+2 more
openalex
Field study on prescription issue for hypotensive drug in Okinawa Prefecture.
H Yoshiwara
openalex +2 more sources
Editorial: Canadian Association on Gerontology Policy Statement: Seniors and Prescription Drugs [PDF]
openalex +1 more source
Objective The objective of this study was to investigate the effect of prophylactic trimethoprim‐sulfamethoxazole (TMP‐SMX) on the incidence of serious infections in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Methods This multicenter cohort study was designed to emulate a target trial that studied 296 patients with ...
Yun Kyu Kim+7 more
wiley +1 more source
Objective Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population ...
Romain Aymon+28 more
wiley +1 more source
Study on the Prescriptions of Drug Interactions in Hospitalized Patients.
Kiyomi Iwai+3 more
openalex +2 more sources
Gout and NLRP3 Inflammasome Biology
This review describes the three broad stages of acute inflammation in the context of gout: initiation, leucocyte mobilization, and self‐resolution. A typical case of a gout flare is presented. The role of the NLRP3 inflammasome in acute monosodium urate crystal–induced inflammation is reviewed in detail.
Raewyn Poulsen, Nicola Dalbeth
wiley +1 more source
Objectives Tumor necrosis factor inhibitors (TNFi) have significantly improved rheumatoid arthritis (RA) management, yet variability in patient response remains a substantial challenge, with approximately 40% of patients discontinuing TNFi due to non‐response or adverse effects. This study aimed to identify biomarkers predictive of adalimumab treatment
Chuan Fu Yap+12 more
wiley +1 more source